Drug, across the briefings
Nintedanib across 13 cancers
Nintedanib appears in 13 of the briefings; no FDA label names any of them.
| Disease | FDA label | Open Targets stage, on which gene | Trials | Active |
|---|---|---|---|---|
| Bladder cancer | approved on FGFR3 | 1 | 0 | |
| Cholangiocarcinoma | approved on FGFR2 | — | — | |
| Gallbladder cancer | approved on FGFR2 | — | — | |
| Gastric cancer | approved on FGFR2, KDR | — | — | |
| Gastrointestinal stromal tumour | approved on PDGFRA | — | — | |
| Glioblastoma | approved on PDGFRA | 3 | 0 | |
| Hepatocellular carcinoma | approved on FGFR4, KDR | 3 | 0 | |
| Kidney cancer | approved on KDR | 1 | 0 | |
| Lower-grade glioma | approved on PDGFRA | — | — | |
| Osteosarcoma | approved on KDR | — | — | |
| Rhabdomyosarcoma | approved on FGFR4 | — | — | |
| Small intestine cancer | approved on PDGFRA | — | — | |
| Soft tissue sarcoma | approved on PDGFRA, PDGFRB | 1 | 0 |
The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.